Watch IOVA. Know when insiders buy.
One email the day a filing lands. Free.
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
10.02
+0.15 +1.52%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
92
PASS · shorts 92
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.5BP/E —DIV YIELD —FCF YIELD -6.53%REV TTM $325M +34.5%NET INCOME −$289.5MNET CASH —52W 1.81 – 10.02SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $99.3M | +65.7% | 56.1% | −$51.9M | −$47.3M | — | -0.11 | −$60.8M | $5.4M | −$66.3M | Aug 6 |
| Q1 2026 · Mar 31 | $71.4M | +44.8% | 40.5% | −$81M | −$79M | — | -0.19 | −$72.1M | $6.6M | −$78.7M | May 7 |
| Q4 2025 · Dec 31derived | $86.8M | +17.7% | 50.3% | −$73.5M | −$71.9M | — | -0.15 | −$52.6M | $9.3M | −$61.9M | Feb 24 |
| Q3 2025 · Sep 30 | $67.5M | +15.2% | 43.0% | −$94.9M | −$91.3M | — | -0.25 | −$78.7M | $10.8M | −$89.5M | Nov 6 |
| Q2 2025 · Jun 30 | $60M | +92.7% | 18.5% | −$113.8M | −$111.7M | — | -0.33 | −$67.4M | $7.5M | −$74.9M | Aug 6 |
| Q1 2025 · Mar 31 | $49.3M | +6798.5% | 13.4% | −$121.2M | −$116.2M | — | -0.36 | −$103.7M | $6.2M | −$109.9M | May 7 |
| Q4 2024 · Dec 31derived | $73.7M | +15189.2% | 48.7% | −$86.6M | −$78.6M | — | -0.25 | −$73.3M | $4.2M | −$77.5M | Feb 24 |
| Q3 2024 · Sep 30 | $58.6M | +12385.1% | 46.2% | −$89.1M | −$83.5M | — | -0.28 | −$59M | $2.3M | −$61.3M | Nov 6 |
| Q2 2024 · Jun 30 | $31.1M | — | -0.8% | −$101.9M | −$97.1M | — | -0.34 | −$98.4M | $442K | −$98.9M | Aug 7 |
| Q1 2024 · Mar 31 | $715K | — | -915.5% | −$117.7M | −$113M | — | -0.42 | −$122.3M | $4.2M | −$126.5M | May 8 |
| Q4 2023 · Dec 31derived | $482K | — | 1211.4% | −$121.3M | −$116.4M | — | -0.45 | −$84M | $3.5M | −$87.5M | Feb 24 |
| Q3 2023 · Sep 30 | $469K | — | -825.4% | −$118.4M | −$113.8M | — | -0.46 | −$84.1M | $3.6M | −$87.7M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $263.5M | 34.3% | −$403.4M | −$391M | -148.4% | -1.09 | −$302.4M | $33.8M | −$336.2M | — | — |
| FY2024 · to Dec 31 | $164.1M | 43.2% | −$395.3M | −$372.2M | -226.8% | -1.28 | −$353M | $11.1M | −$364M | — | — |
| FY2023 · to Dec 31 | $1.2M | 13.1% | −$460.6M | −$444M | -37345.4% | -1.89 | −$361.8M | $22.3M | −$384.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$398.9M | −$395.9M | — | -2.49 | −$292.8M | $20.4M | −$313.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$342.7M | −$342.3M | — | -2.23 | −$227.9M | $37.6M | −$265.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$261.9M | −$259.6M | — | -1.88 | −$205.1M | $46.8M | −$251.9M | — | — |
Every number comes from IOVANCE BIOTHERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.